FMA
IOVA icon

FNY Managed Accounts’s Iovance Biotherapeutics IOVA Stock Holding History

FNY Managed Accounts’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-6,000
Closed -$55K – 498
2015
Q2 		$55K Buy
+6,000
New +$67K 0.07% 150

Other funds holding IOVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

FNY Managed Accounts's IOVA Position: Q3 2015 in Review

FNY Managed Accounts sold out of Iovance Biotherapeutics (IOVA) in Q3 2015, closing a stake of 6,000 shares — an estimated $55K sold.

FNY Managed Accounts first reported a position in IOVA in Q2 2015 and held it in 1 quarter. The position peaked at $55K in Q2 2015. 80 funds tracked by Wall St. Rank hold IOVA as of Q3 2015.

  • FNY Managed Accounts reported no remaining Iovance Biotherapeutics position as of Q3 2015 after selling out during the quarter.
  • FNY Managed Accounts sold 6,000 Iovance Biotherapeutics shares in Q3 2015, an estimated $55K.
  • FNY Managed Accounts first reported a position in Iovance Biotherapeutics in Q2 2015 and held it in 1 quarter.
  • FNY Managed Accounts's Iovance Biotherapeutics position peaked at $55K in Q2 2015.
  • 80 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2015.

Based on FNY Managed Accounts's 13F filing for Q3 2015, filed 27 Oct 2015.